These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2962589)

  • 21. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
    Chaisson RE; Leuther MD; Allain JP; Nusinoff-Lehrman S; Boone GS; Feigal D; Volberding P
    Arch Intern Med; 1988 Oct; 148(10):2151-3. PubMed ID: 3263098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The present status in prophylaxis and treatment of HIV infected patients with hemophilia in Japan].
    Mori K; Sakai H; Suzuki S; Akutsu Y; Ishikawa M; Aihara M; Yokoyama M; Sato Y; Okaniwa S; Endo Y
    Rinsho Byori; 1989 Nov; 37(11):1200-8. PubMed ID: 2689699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group.
    Parente F; Bianchi Porro G
    Am J Gastroenterol; 1998 Mar; 93(3):317-22. PubMed ID: 9517631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of Epstein-Barr virus antigens and DNA-polymerase activities in P3HR-1 cell line and its subline passaged in the presence of phosphonoformate.
    Prachová K; Roubal J; Vonka V; Brichácek B; Reifová M
    Acta Virol; 1983 Jul; 27(4):329-36. PubMed ID: 6138996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of HTLV-III/LAV-infected patients with D-penicillamine.
    Schulof RS; Scheib RG; Parenti DM; Simon GL; DiGioia RA; Paxton HM; Sztein MB; Chandra P; Courtless JW; Taguchi YT
    Arzneimittelforschung; 1986 Oct; 36(10):1531-4. PubMed ID: 2949756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS).
    Shearer GM; Bernstein DC; Tung KS; Via CS; Redfield R; Salahuddin SZ; Gallo RC
    J Immunol; 1986 Oct; 137(8):2514-21. PubMed ID: 3489767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
    Arch Intern Med; 1995 Jan; 155(1):65-74. PubMed ID: 7802522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predominance of HIV-1 among patients with AIDS and AIDS-related complex in Ghana.
    Brandful JA; Ampofo WK; Apeagyei FA; Asare-Bediako K; Osei-Kwasi M
    East Afr Med J; 1997 Jan; 74(1):17-20. PubMed ID: 9145571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of extended peptide T administration in AIDS and ARC patients.
    Bridge TP; Heseltine PN; Parker ES; Eaton EM; Ingraham LJ; McGrail ML; Goodwin FK
    Psychopharmacol Bull; 1991; 27(3):237-45. PubMed ID: 1775594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Foscarnet and extended survival in AIDS patients.
    Am Fam Physician; 1991 Dec; 44(6):2244. PubMed ID: 1836090
    [No Abstract]   [Full Text] [Related]  

  • 34. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New treatment being tested against AIDS and ARC.
    Oncology (Williston Park); 1987 Sep; 1(7):11. PubMed ID: 2856351
    [No Abstract]   [Full Text] [Related]  

  • 36. Isoprinosine (inosine pranobex BAN, INPX) in the treatment of AIDS and other acquired immunodeficiencies of clinical importance.
    Glasky AJ; Gordon JF
    Cancer Detect Prev Suppl; 1987; 1():597-609. PubMed ID: 2446760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Isolation of LAV/HTLV III from tears of patients with the ARC syndrome].
    Baudouin C; Laffont C; Cottalorda J; De Galleani B; Gastaud P; Lefebvre JC
    J Fr Ophtalmol; 1987; 10(2):135-9. PubMed ID: 2440938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine.
    Youle MS; Clarbour J; Gazzard B; Chanas A
    Lancet; 1988 Jun; 1(8600):1455-6. PubMed ID: 2898602
    [No Abstract]   [Full Text] [Related]  

  • 39. AIDS: the virus, antivirals and vaccines.
    Weber J
    Br J Hosp Med; 1987 Feb; 37(2):135-7, 140-1. PubMed ID: 2950962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in the development of antiviral therapy for HTLV-III-associated diseases.
    Yarchoan R; Broder S
    Important Adv Oncol; 1987; ():293-311. PubMed ID: 2841232
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.